I

Intuitive Surgical

Builds robots for minimally invasive surgery

Staff Biostatistician

Full-TimeUpdated on 10/23/2026
$162.7k - $260.1k
Expert
Master's, PhD
Sunnyvale, CA, USA
RemoteRemote OK; onsite preference in Sunnyvale, California. Up to 10% travel.
Biology & BiotechQuantitative Biology & Biostatistics

About the job

Requirements
  • A Master's (MS) or Ph.D. in Biostatistics or Statistics is required.
  • A minimum of 9 years of experience with an MS, or 6 years with a Ph.D., is required.
  • A minimum of 5 years of clinical trial experience is required.
  • A minimum of 5 years of medical device experience is required.
  • Demonstrate a track record of developing and applying innovative, integrative biostatistical methodology to problems standard approaches do not solve, with depth across several of the following: adaptive and group-sequential designs, Bayesian methods, historical or external controls, survival and longitudinal modeling, hierarchical models, multiplicity control, missing data and sensitivity analysis, and analysis of large real-world datasets.
  • Mastery of R is required. Demonstrate the ability to set programming standards, write clean, functional, modular, well-tested code in a shared development environment, and lead by example in code review and validation practice.
  • Be fluent in version control with Git in a GxP-validated environment for reproducible analyses ready for regulatory compliance audits.
  • Demonstrate experience applying frontier AI models to expand productivity across the biostatistician job function, with specific, verifiable examples of redesigned workflows and quantified gains in cycle time, throughput, or quality. Be able to drive team adoption by establishing patterns, tooling, and human-in-the-loop verification controls for reliable, reproducible, compliant AI-assisted work in an international GxP environment.
  • Operate independently, set direction for others, resolve ambiguity without escalation, and be accountable for the technical quality of a multi-project portfolio.
  • Have an established reputation and sustained relationships within the external biostatistics, medical device, clinical trials, and regulatory communities, with a record of independent contribution.
  • Demonstrate strong scientific writing and editing skills, attention to detail, scientific integrity, and communication with technical and non-technical constituents, senior leadership, and external audiences.
  • Be willing to travel up to 10%.
  • Candidates who do not reside, or plan to reside, in Alabama, Arkansas, Delaware, Florida, Indiana, Iowa, Louisiana, Maryland, Mississippi, Missouri, Oklahoma, Pennsylvania, South Carolina, or Tennessee are preferred; candidates able to be onsite in Sunnyvale, California or willing to relocate are also preferred.
Responsibilities
  • Set the statistical vision and direction for design, conduct, and analysis of clinical studies from early feasibility through pivotal pre-market trials and post-market evidence generation.
  • Own multiple business or functional areas and a portfolio of ten or more concurrent projects; set programming and analysis standards, develop training curricula, standard operating procedures, and work instructions, and represent Biostatistics with regulatory agencies, principal investigators, key opinion leaders, and the scientific community.
  • Develop statistical approaches for complex clinical protocols, including Bayesian and frequentist design selection, endpoint and estimand framing, hypothesis tests, power analyses, sample-size justification, randomization design and review, and adaptive or interim analysis strategy.
  • Serve as the final internal statistical authority for design decisions across owned studies and advise on design trade-offs at program and platform levels.
  • Serve Data Monitoring Committees and Data and Safety Monitoring Boards as the unblinded sponsor statistician.
  • Set the vision and direction for statistical analysis plans and mock Tables, Listings, and Figures across the portfolio; define departmental standards, templates, and the degree of pre-specification; review and approve others' work against those standards.
  • Set the direction for clinical trial data analysis, select and champion methodologies, and ensure analyses are reproducible, defensible, and suitable for regulatory and peer review.
  • Own the portfolio's most complex or novel analytical problems and direct interim analyses, database lock, and unblinding activities according to study requirements.
  • Manage a portfolio of ten or more projects simultaneously, take ownership of multiple business or functional areas, set priorities, sequence work, and allocate statistical effort.
  • Represent Biostatistics and serve as a strategic partner in core-team and program-level forums; shape evidence-generation strategy across surgical specialties and product platforms, set execution roadmaps, and manage timelines and stakeholder expectations.
  • Influence senior leadership as a strategic thought partner; translate statistical complexity into clear, actionable direction with clinical and business implications; lead meetings and set agendas for the biostatistics team.
  • Write or edit methods, results, and interpretation sections for studies supporting regulatory submissions, compliance documents, scientific journals, and medical conferences.
  • Conduct additional research as needed to generate clinical evidence, including analyses of large clinical or administrative databases, systematic literature reviews, and meta-analyses.
  • Keep current with biostatistical methodology and apply developments to improve study design, analysis, and reporting; contribute independently to the scientific community through peer-reviewed publications, conference presentations, and methodological contributions.
  • Represent Biostatistics in direct interactions with regulatory agencies, principal investigators, key opinion leaders, and external statisticians, including responding to regulatory questions about statistical design and analysis for pre-approval, post-approval, and post-market clinical follow-up studies.
  • Build and sustain external relationships and serve as a thought leader in the field.
  • Co-strategize with Data Management on data quality, consistency, scalability, and traceability; specify CDISC-aligned SDTM and ADaM data structures and analysis-ready dataset specifications.
  • Set departmental programming and analysis standards, lead by example in code and deliverables, and implement standards across the department.
  • Develop and own standard operating procedures and work instructions to standardize, validate, and quality-control analysis pipelines for regulatory submissions and scientific publications.
  • Set the biostatistics training curriculum and deliver training in biostatistical methodology and programming practice.
  • Provide technical leadership and career-development guidance to statisticians at junior levels.
  • Oversee and direct external statistical vendors and contract research organizations.
  • Ensure activities comply with Good Clinical Practice, ISO 14155, ICH E9, ICH E6, and 21 CFR Part 812; apply relevant FDA guidance, including guidance on adaptive designs and Bayesian methods for medical device trials.
Desired Qualifications
  • Experience in surgical and robotic-assisted device clinical research is strongly preferred.
  • Proficiency in SAS and Python is valued.

About the company

Intuitive Surgical makes da Vinci robots that let surgeons operate through a few small incisions, and Ion, a robot that reaches deep into the lungs to take tissue samples. In 2000, da Vinci became the first robotic system cleared by the FDA for general laparoscopic surgery, meaning keyhole operations in the abdomen. A surgeon sits at a nearby console and steers robotic arms holding a 3D camera and wristed instruments, which turn hand movements into smaller, steadier motions. Hospitals buy or lease the robots, then keep paying for the instruments used in each operation and for service. Intuitive was founded in 1995 to commercialize robotic surgery research from SRI International and is based in Sunnyvale, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Sunnyvale, California

Founded

1995

Get referred to Intuitive Surgical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Demand keeps compounding: da Vinci procedures grew 15% and revenue 19%, to $2.89 billion, in the June 2026 quarter.
  • Room to grow: Intuitive listed 748 open roles in October 2026, including 191 in engineering and 312 in Sunnyvale.
  • Repeat sales steady the business: instruments and service made 76% of revenue in the June 2026 quarter.

What critics are saying

  • Stock grants have shrunk: shares fell 27% from January to October 2026, versus 9% for rival Medtronic.
  • Device giants are moving in: the FDA cleared rival robots from Medtronic in December 2025 and J&J in July 2026.
  • Instrument sales face a court fight: in August 2026, an appeals court revived a repair firm's monopoly suit against Intuitive.

What makes Intuitive Surgical unique

  • Hospitals rent more than they buy: 254 of 468 da Vinci systems placed in the June 2026 quarter were leases.
  • It runs without borrowing: Intuitive had no debt and $8.6 billion in cash and investments in June 2026.
  • Its CEO is a 30-year insider: Dave Rosa, CEO since July 2025, joined as employee number nine in 1996.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Hybrid Work Options

Growth & Insights and Company News

6 month growth

0%

1 year growth

0%

2 year growth

0%
Yahoo Finance
Oct 1st, 2026
Intuitive Surgical down 30% in 2026, but Wall Street analysts stay bullish

Intuitive Surgical has lost nearly 30% year-to-date in 2026, making it one of healthcare's biggest losers. The stock fell over 40% by late July. Despite this decline, Wall Street remains bullish—24 of 32 analysts surveyed by S&P Global in September rated it a "buy" or "strong buy." The medical device maker faces several challenges. Growth is slowing whilst the stock trades at a forward price-to-earnings multiple over 33. Competition in China remains difficult, and the company now battles healthcare giants Johnson & Johnson, Medtronic, and Stryker in robotic surgical systems. The expiration of Affordable Care Act subsidies and rising GLP-1 drug usage have also impacted procedure volumes. However, the company's Asian revenue still jumped 20% year-over-year in Q2, suggesting these headwinds aren't insurmountable.

Yahoo Finance
Sep 17th, 2026
Intuitive Surgical, IonQ, and Accenture hold billions in net cash for growth

Investors seeking financial stability often look to companies with more cash than debt, as these businesses have greater flexibility for growth investments, buybacks, and dividends. Intuitive Surgical holds $5.22 billion in net cash. The robotic surgery pioneer achieved 20.7% annual revenue growth over the past two years, whilst its earnings per share increased 17.4% annually over five years. IonQ maintains $2.06 billion in net cash, representing 14.1% of its market capitalisation. The quantum computing company posted 181% annual revenue growth over two years and expects 163% growth next year. Accenture has $1.78 billion in net cash. The professional services firm employs approximately 774,000 people across more than 120 countries. Companies with strong balance sheets can navigate uncertain markets whilst pursuing expansion opportunities without the burden of significant debt obligations.

Yahoo Finance
Aug 23rd, 2026
Thermo Fisher vs Intuitive Surgical: which premium healthcare stock justifies valuation?

Thermo Fisher and Intuitive Surgical both delivered strong recent quarters, but their premium valuations rest on different foundations. Thermo Fisher's case depends on recovery in life sciences spending after the pandemic slowdown. The company's Life Sciences Solutions segment saw reported revenue climb 13% year-over-year, with organic revenue up 3%. The Analytical Instruments business returned to growth after nearly two years of weak demand, suggesting laboratory spending is normalising. Intuitive Surgical maintains its premium through business model strength. The company's non-GAAP gross profit margin reached 70.0%, whilst its non-GAAP operating margin expanded 330 basis points year-over-year to 42.1%. Recurring revenue streams constitute roughly 85% of total sales. Intuitive placed 468 da Vinci surgical units in fiscal Q2, marking 18% year-over-year growth, indicating continued hospital investment in robotic surgery platforms.

Yahoo Finance
Aug 19th, 2026
Abbott beats Q2 estimates with 13% sales growth as diagnostics surge 42%, while Intuitive Surgical posts 19% revenue rise

Abbott Laboratories reported strong fiscal Q2 2026 results, with sales rising 13% on a reported basis and 4.8% on a comparable basis, beating estimates and prompting the company to raise its annual profit forecast. The diagnostics segment was particularly strong, growing 42% to $3.09 billion, driven by its cancer diagnostics business following the Exact Sciences acquisition. Intuitive Surgical also exceeded expectations in Q2 2026, with revenue growing 19% to $2.89 billion and adjusted EPS of $2.80, beating forecasts by $0.30. The company placed 468 da Vinci units during the quarter, an 18% year-over-year increase, whilst maintaining a non-GAAP gross margin of 70.0%. The companies present contrasting investment cases: Abbott offers diversified healthcare portfolio resilience, whilst Intuitive Surgical relies on its robotic surgery ecosystem with recurring revenue comprising approximately 85% of total sales.

PR Newswire
Aug 17th, 2026
Intuitive leases 316,000-sq-ft facility in Penang to manufacture surgical instruments, create 1,200 jobs by 2032

Intuitive, the global leader in minimally invasive care and pioneer of robotic-assisted surgery, has signed a lease agreement with Penang Development Corporation for a new manufacturing facility in Malaysia. The 316,000-square-foot site in Bandar Cassia Technology Park will produce surgical instruments and electromechanical devices for Intuitive's da Vinci surgical system. The facility is expected to begin operations in 2028 and create 1,200 highly skilled jobs by 2032. The investment reflects Intuitive's commitment to Asia Pacific, where its da Vinci systems have treated more than 2.5 million patients across 13 markets over two decades. The expansion aims to support growing demand for robotic-assisted surgery across the region and strengthen Penang's position as a MedTech manufacturing hub in Southeast Asia.